SCHEDULE: Akari Therapeutics: Dr. Prudo Boosts Stake to 8.9%

Dr. Ray Prudo and affiliated entities have increased their beneficial ownership in Akari Therapeutics Plc to 8.9% following recent private placement transactions.

Summary

• This Amendment No. 10 to Schedule 13D updates beneficial ownership information for Akari Therapeutics Plc.
• The reporting persons are Dr. Ray Prudo, RPC Pharma Limited, and Praxis Trustees Limited.
• Dr. Prudo's aggregate beneficial ownership is 8,391,326,467 Ordinary Shares, representing 8.9% of the class.
• This includes shares held directly by Dr. Prudo, options exercisable within 60 days, prefunded warrants exercisable within 60 days, and shares held by RPC Pharma Limited and Praxis Trustees Limited, which Dr. Prudo controls.
• RPC Pharma Limited beneficially owns 800,766,600 Ordinary Shares, representing 0.87% of the class.
• Praxis Trustees Limited beneficially owns 38,709,600 Ordinary Shares, representing 0.042% of the class.
• The percentage of ownership is based on 91,567,009,533 Ordinary Shares issued and outstanding as of March 1, 2026.
• On December 17, 2025, Dr. Prudo purchased 618,658 Series G Warrants and 618,658 Pre-Funded Warrants (representing 1,237,316,000 Ordinary Shares) at a combined price of $0.4041 per warrant pair in a private placement.
• On the same date, Dr. Prudo also purchased 386,661 Note Exchange Warrants and 618,658 Pre-Funded Warrants (representing 773,322,000 Ordinary Shares) at a combined price of $0.4041 per warrant pair through a note cancellation and exchange agreement.
• The funds used by Dr. Prudo for these acquisitions were from his personal funds.
• Each American Depositary Share (ADS) represents 2,000 Ordinary Shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the significant insider buying by Dr. Prudo using personal funds, which signals strong confidence in the company's future, despite the filing being a routine ownership update.

Positives

• Increased beneficial ownership by a key insider (Dr. Ray Prudo) demonstrates continued confidence in Akari Therapeutics.
• Dr. Prudo used personal funds for the recent securities purchases, indicating a direct financial commitment to the company.

Risks

• Warrants issued to Dr. Prudo are subject to a 9.99% beneficial ownership limitation, which could restrict further immediate accumulation of shares through warrant exercise if it exceeds this threshold.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the exercise periods of warrants and options.

Management Comments

• Dr. Prudo controls the voting and investment decisions with respect to the shares held of record by RPC and Praxis and thereby may be deemed the beneficial owner of such shares.

Industry Context

StockSavvy.ai notes that increased insider ownership, particularly through direct purchases using personal funds, can signal strong internal confidence in a company's future prospects, especially in the volatile biotech sector where capital raises and clinical milestones are critical. This move by Dr. Prudo could be interpreted positively by the market, suggesting a belief in Akari's pipeline or strategic direction.

Comparison to Industry Standards

• Insider buying, especially by a significant shareholder like Dr. Prudo, is generally viewed as a positive signal, aligning management/insider interests with those of public shareholders. For example, similar significant insider purchases have been observed in other small-cap biotech firms like Atea Pharmaceuticals (AVIR) or Vaxart (VXRT) following key developments, often preceding periods of increased investor interest.
• The use of warrants and pre-funded warrants in a private placement is a common financing mechanism for biotech companies, allowing for capital infusion while potentially deferring full dilution. This structure is comparable to financing rounds seen in companies like Sorrento Therapeutics (SRNE) or Cassava Sciences (SAVA) in their earlier stages, where strategic investors often participate through similar instruments.

Related Party Transactions

• Dr. Ray Prudo, a reporting person, participated in the December 2025 PIPE and a note cancellation and exchange agreement with Akari Therapeutics Plc, purchasing warrants.
• Dr. Prudo controls RPC Pharma Limited and Praxis Trustees Limited, which also hold shares of the Issuer.

Stakeholder Impact

• Shareholders: Increased insider ownership may instill confidence, potentially signaling a positive outlook from a key stakeholder. The private placement structure could lead to future dilution upon warrant exercise.
• Creditors: The note cancellation and exchange agreement could impact the company's debt structure, though specific details on the original note are not provided in this amendment.

Key Dates

Recommendation

While the increased insider ownership by Dr. Prudo is a positive signal, demonstrating confidence and a personal financial commitment, this filing primarily updates ownership percentages following a private placement. It does not provide new operational or financial performance data that would warrant a 'buy' or 'sell' recommendation. The stock's performance will ultimately depend on Akari Therapeutics' clinical pipeline progress and financial results, which are not detailed here. Therefore, a 'hold' recommendation is appropriate for investors to await further fundamental updates.

Keywords

Akari Therapeutics, AKTX, Schedule 13D, beneficial ownership, insider buying, private placement, warrants, pre-funded warrants, Dr. Ray Prudo, SEC filing, biotech, pharmaceutical